Pharma's Almanac: Nice Insight's Content Community

Enzymes

Enzymes

M&A

Enzymaster’s Sanming Minhe Acquisition Increases Production Capacity by 50% to Keep Pace with Rapidly Growing Demand

Enzymaster

Drug Development

A New Approach for Diseases Associated with BH4-Dependent Enzymatic Pathways

Jonathan Reis, Ph.D.

Chiral Synthesis

Applying Enzymatic Synthesis for Chiral Molecules

Juliette Martin, Ph.D.; Sergio Kreimerman, Ph.D.

Seqens

Launch

New England Biolabs® Launches NEBNext® Enzymatic Methyl-seq (EM-seq™) for Bisulfite-Free Methylation Analysis

New England Biolabs

FDA Fast Track

Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations

Enzyvant

Cell and Gene Therapy

BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

BridgeBio Pharma

Drug Discovery

RNA-Modifying Proteins May Provide New Drug Targets

Guy Tiene

Nice Insight

Acquisition

Almac Expands Analytical Services with BioClin Laboratories Acquisition

Nice Insight

M&A

Enzymaster’s Sanming Minhe Acquisition Increases Production Capacity by 50% to Keep Pace with Rapidly Growing Demand

Enzymaster

Drug Development

A New Approach for Diseases Associated with BH4-Dependent Enzymatic Pathways

Jonathan Reis, Ph.D.

Chiral Synthesis

Applying Enzymatic Synthesis for Chiral Molecules

Juliette Martin, Ph.D.; Sergio Kreimerman, Ph.D.

Seqens

Launch

New England Biolabs® Launches NEBNext® Enzymatic Methyl-seq (EM-seq™) for Bisulfite-Free Methylation Analysis

New England Biolabs

FDA Fast Track

Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations

Enzyvant

Cell and Gene Therapy

BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

BridgeBio Pharma

Drug Discovery

RNA-Modifying Proteins May Provide New Drug Targets

Guy Tiene

Nice Insight

Acquisition

Almac Expands Analytical Services with BioClin Laboratories Acquisition

Nice Insight